California AB-1990 and Access to Compounded GLP-1s
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
California Assembly Bill 1990 is a pending state bill that would raise the ingredient, record keeping, and advertising standards that licensed compounding pharmacies in California must follow when preparing GLP-1 weight loss medications. It has cleared one committee and is still moving through the legislative process.
Who This Helps
This one is for you if you are a California patient on a compounded GLP-1 medication, you are thinking about starting one, or you want to understand how new state laws may shape your telehealth and pharmacy options. It is also useful for GLP-1 patients outside California who want a plain-language look at how state legislation around compounded products is changing.
What AB-1990 Would Do in Plain Language
AB-1990 focuses on compounded drugs that contain a GLP-1 receptor agonist, which is the medical term for medications that activate a receptor in your body that helps with blood sugar and appetite (California Legislative Information). Put simply, the bill would require licensed compounding pharmacies in California to do four things when preparing these medications, each of which adds a layer on top of what current federal and state rules already require.
- Use pharmaceutical-grade bulk ingredients that come with a certificate of analysis from the supplier. Licensed compounders today are expected to use ingredients that meet pharmaceutical standards, but documentation practices vary from pharmacy to pharmacy. The bill would make a per-batch certificate of analysis an explicit, enforceable requirement in California (California Legislative Information).
- Source those ingredients from FDA-registered facilities that have been inspected recently. Federal law already requires ingredient suppliers for 503A compounding to be FDA-registered. The new piece is the "recently inspected" standard, since a supplier can currently be registered with the FDA without having been inspected in years. The pharmacy would need to confirm inspection status as part of its sourcing paperwork.
- Keep detailed records of where each ingredient came from, how it was tested, and when it was used, for at least 2 years after the medication expires. Licensed pharmacies already keep compounding records under USP 795, USP 797, and California Board of Pharmacy rules, but record retention periods and granularity vary. The bill sets a uniform 2-year floor that runs from the product's expiration rather than from the compounding date, which stretches the record window longer than most current baselines.
- Make sure any advertising for the compounded medication is truthful, discloses side effects, and clearly states that the product is compounded and has not been FDA-approved. California already prohibits false advertising in general. The bill would add specific disclosure requirements for compounded GLP-1 products, including a side-effect disclosure and an explicit "this product is compounded, FDA-unapproved, and not evaluated for safety or efficacy" statement, which lines up with recent FDA enforcement language on this kind of marketing.
If a pharmacy falls out of line with these rules, the bill proposes a fine of $1,000 per dose sold and potential license revocation by the California State Board of Pharmacy (California Legislative Information).
What this means for you: The bill targets the pharmacy and the supply chain. Your doctor can still prescribe a compounded GLP-1 medication if the bill passes. What would change is the paperwork and sourcing standards your pharmacy has to meet.
Current Status as of April 2026
AB-1990 was introduced on February 17, 2026 and amended on April 15, 2026 (California Legislative Information). On April 14, 2026 the bill passed the Assembly Business and Professions Committee by a 17 to 1 vote and moved to the Assembly Privacy and Consumer Protection Committee for its next hearing. The bill still has to clear additional committees, the full Assembly, the Senate, and the Governor's signature before it becomes law, which is a path that usually takes months, and the language often shifts along the way.
Why This Is Happening Now
The federal backdrop shapes why California is moving on this. When the FDA declared that the tirzepatide shortage had ended on December 19, 2024 and the semaglutide shortage had ended on February 21, 2025, the legal room for compounding these medications at the federal level narrowed (FDA). During the same window, law enforcement and consumer groups reported more cases of contaminated ingredients, dosing errors, and misleading advertising tied to some telehealth and compounding operations (FDA). States began writing their own rules to fill gaps that the federal framework left open, and AB-1990 is one of those efforts. The bill's authors have described it as a consumer protection measure meant to raise the floor on quality and transparency (California Legislative Information).
How It Would Affect Compounding Pharmacies
The practical impact depends on the type of pharmacy. 503A community compounding pharmacies, which are state-licensed and prepare medications for individual prescriptions, would need to build supply chain verification systems, run or document quality control testing, and keep longer records. Small independent pharmacies may find the new lift harder and more expensive than larger ones. 503B outsourcing facilities already follow FDA manufacturing standards, so the bar for them is lower, though they would still be on the hook for documenting and passing along proof of pharmaceutical grade ingredients to any 503A pharmacies they supply. The GLP Winner article on how compounding pharmacies are regulated has more on the distinction between these two types.
Trade groups have pushed back on the bill. The Alliance for Pharmacy Compounding has testified that some of the new documentation requirements would go beyond what federal law and the U.S. Pharmacopeia already require (Alliance for Pharmacy Compounding). The Chamber of Progress has argued that the bill could narrow patient access to clinician-supervised compounded medications (Chamber of Progress).
What this means for you: If the bill becomes law, some California compounding pharmacies may step back from preparing GLP-1 medications, and others will continue with new steps in the process. The ones that continue will have more paperwork backing up what they dispense.
How It Could Affect Your Access in California
For California patients using a compounded GLP-1 medication, a few likely shifts come with the bill if it passes.
- Some pharmacies may leave this market, which could make supply tighter in parts of the state with fewer options.
- Compounded GLP-1 prices may rise to cover new compliance costs.
- Advertising should read clearer, with product status, side effects, and pricing laid out in plain language up front.
- Access to brand-name FDA-approved products like Ozempic, Wegovy, Mounjaro, and Zepbound continues under federal approval and your insurance coverage.
A few GLP Winner resources are useful if you want to dig deeper:
- The article on 503A vs 503B compounding pharmacies walks through the differences so you can understand how your current pharmacy fits into this framework.
- The GLP Winner provider survey matches you with providers that publish clinician names, pharmacy details, and pricing up front.
- The guide on evaluating telehealth and compounded GLP-1 providers helps you work through the decision step by step.
- California had separate state coverage changes take effect in January 2026, which are tracked in the GLP Winner article on state-level GLP-1 coverage changes in 2026.
Similar Bills in Other States
California is part of a broader wave. Several states are weighing similar legislation in 2026.
- Florida Senate Bill 860 would restrict the sale of compounded weight loss medications unless the ingredients are identical to those in FDA-approved drugs and come from FDA-registered facilities inspected within 2 years, with a proposed $1,000 per dose fine (Florida Senate).
- Colorado Senate Bill 26-066 would require certificates of analysis, FDA-inspected ingredient sources, and label warnings for compounded weight loss medications, with fines up to $1,000 per dose. It passed the Colorado Senate on April 17, 2026 on a 20 to 15 vote and moved to the House for consideration (Colorado General Assembly, CBS Colorado).
- Indiana Senate Bill 282 tightens compounding rules for GLP-1 substances used for weight management and creates registration requirements for medical spas. It was signed into law with an effective date of July 1, 2026 (Indiana General Assembly).
Even outside California, watching your state board of pharmacy is a reasonable habit over the next year.
The Bill's Reach Is Narrower Than Some Headlines Suggest
AB-1990 applies to one specific thing: compounded GLP-1 medications prepared by licensed pharmacies in California. The enforcement mechanism targets pharmacies that fall short on ingredient sourcing, record keeping, or advertising standards, with fines up to $1,000 per dose.
Outside that scope, normal practice continues. Licensed clinicians can keep writing prescriptions for compounded GLP-1 medications. FDA-approved brand medications like Ozempic, Wegovy, Mounjaro, and Zepbound stay governed by federal approval and your insurance coverage. Federal FDA enforcement authority continues on its own track, independent of California law. And the patient side of the relationship stays the patient side, since enforcement is directed at the pharmacy.
Language to Watch For
While a bill like this is in progress, some social media and ad messaging tends to overshoot in either direction. A few phrases worth slowing down on:
- "California is banning compounded GLP-1s." The bill raises ingredient and advertising standards rather than taking compounded products off the market, which is a real distinction worth making. Pharmacy and healthcare journalism outlets have flagged that early reporting on state compounding bills sometimes blurs standards-raising legislation with outright bans (Association of Health Care Journalists).
- "AB-1990 is already law." As of April 21, 2026, the bill has passed one committee and is still moving through the legislative process, with several more stages to clear before it could take effect (California Legislative Information).
- "This protects you from a dangerous product." Compounded medications from licensed 503A and 503B pharmacies follow different rules than unregulated or gray market products, and the bill raises quality standards on top of existing state and federal rules (FDA Compounding Q&A). Industry and trade groups have also noted that conflating licensed compounding with illegal online sales can mislead readers (Alliance for Pharmacy Compounding).
Final Takeaway
AB-1990 is a work in progress. If it passes, it would sit on top of existing federal rules and would push California compounding pharmacies to document more about where their ingredients come from and how they describe what they sell. Some California patients may see higher prices or fewer local pharmacy options, and many will see clearer labels and steadier quality from the pharmacies that continue. Your FDA-approved brand options stay the same. The steady move is to know which kind of pharmacy fills your medication, keep your clinician in the loop, and watch how the bill moves at its next committee hearing.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Sources
Keep Reading
FDA statements, tariffs, and lawsuits have compounded GLP-1 patients' worries. Here is what is changing, what is not, and what it means for your price
Which GLP-1 medications are FDA-approved for weight management vs diabetes? Clear labels, approved uses, and common misconceptions explained.
The FDA warned about counterfeit Ozempic, research peptides, and retatrutide. Medications should be prescribed and filled by state-licensed pharmacies
Proposed state and federal compounding laws could affect GLP-1 access in 2026. Here’s what’s changing and why it matters.
Curated by
